CN111909095B - 苯酰甲硝唑的合成方法 - Google Patents
苯酰甲硝唑的合成方法 Download PDFInfo
- Publication number
- CN111909095B CN111909095B CN202010785268.6A CN202010785268A CN111909095B CN 111909095 B CN111909095 B CN 111909095B CN 202010785268 A CN202010785268 A CN 202010785268A CN 111909095 B CN111909095 B CN 111909095B
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- solvent
- reaction
- catalyst
- esterification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CUUCCLJJOWSASK-UHFFFAOYSA-N metronidazole benzoate Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOC(=O)C1=CC=CC=C1 CUUCCLJJOWSASK-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229960002476 metronidazole benzoate Drugs 0.000 title claims abstract description 30
- 238000010189 synthetic method Methods 0.000 title claims abstract description 7
- 238000005886 esterification reaction Methods 0.000 claims abstract description 36
- 239000002904 solvent Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 28
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960000282 metronidazole Drugs 0.000 claims abstract description 21
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003054 catalyst Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000032050 esterification Effects 0.000 claims abstract description 14
- 239000003444 phase transfer catalyst Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 239000012043 crude product Substances 0.000 claims description 21
- 238000001816 cooling Methods 0.000 claims description 18
- 239000012074 organic phase Substances 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000000967 suction filtration Methods 0.000 claims description 12
- 229960001701 chloroform Drugs 0.000 claims description 11
- 238000004821 distillation Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 238000001308 synthesis method Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000007670 refining Methods 0.000 claims description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 4
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 238000004042 decolorization Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000003828 vacuum filtration Methods 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 43
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 21
- 239000002253 acid Substances 0.000 abstract description 9
- 239000011230 binding agent Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003513 alkali Substances 0.000 abstract description 5
- 230000007062 hydrolysis Effects 0.000 abstract description 3
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 13
- 238000011084 recovery Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 231100000086 high toxicity Toxicity 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- -1 pyridine Chemical class 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- KLBOFRLEHJAXIU-UHFFFAOYSA-N tributylazanium;chloride Chemical compound Cl.CCCCN(CCCC)CCCC KLBOFRLEHJAXIU-UHFFFAOYSA-N 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 208000006503 Amebic Liver Abscess Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010063741 Hepatic amoebiasis Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010046704 Urogenital trichomoniasis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010785268.6A CN111909095B (zh) | 2020-08-06 | 2020-08-06 | 苯酰甲硝唑的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010785268.6A CN111909095B (zh) | 2020-08-06 | 2020-08-06 | 苯酰甲硝唑的合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111909095A CN111909095A (zh) | 2020-11-10 |
| CN111909095B true CN111909095B (zh) | 2022-02-18 |
Family
ID=73287245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010785268.6A Active CN111909095B (zh) | 2020-08-06 | 2020-08-06 | 苯酰甲硝唑的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111909095B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119823034A (zh) * | 2024-12-06 | 2025-04-15 | 华中药业股份有限公司 | 一种甘露六烟酯的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096834A (en) * | 1997-04-04 | 2000-08-01 | Monsanto Company | Hydrolyzable delivery system using crosslinked polymeric resins as vehicles |
| CN102875476B (zh) * | 2012-09-18 | 2015-01-14 | 湖北省宏源药业有限公司 | 一种苯酰甲硝唑的制备方法 |
| CN109053581B (zh) * | 2018-07-19 | 2023-02-17 | 湖北省宏源药业科技股份有限公司 | 一种苯酰甲硝唑的制备方法 |
-
2020
- 2020-08-06 CN CN202010785268.6A patent/CN111909095B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111909095A (zh) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111747887B (zh) | 一种马来酸氯苯那敏的制备方法 | |
| CN102050737B (zh) | 一种截短侧耳素的提取纯化方法 | |
| CN111909095B (zh) | 苯酰甲硝唑的合成方法 | |
| KR101849376B1 (ko) | 이무수당의 회수 및 정제 | |
| CN111518057A (zh) | 一种安赛蜜结晶液纯化处理方法 | |
| CN112358514B (zh) | 一种熊果苷的合成工艺 | |
| CN100484930C (zh) | 一种吗替麦考酚酯的制备方法 | |
| CN101560188B (zh) | 2-甲基咪唑结晶不纯物的分离纯化方法 | |
| CN109053581B (zh) | 一种苯酰甲硝唑的制备方法 | |
| CN116768910B (zh) | 一种利福布汀的精制方法 | |
| CN115417755B (zh) | 一种3,4-二羟基-2,5-己二酮的纯化及其环化工艺 | |
| CN103664848B (zh) | 一种霉酚酸的提取方法 | |
| CN114315627B (zh) | 常温离子液体和沸石催化合成多西环素脱水物的方法 | |
| CN116554140B (zh) | 一种丙交酯的精制方法 | |
| CN106588888B (zh) | 一种制备高纯度l-苹果酸舒尼替尼的方法 | |
| CN114933588A (zh) | 雷贝拉唑钠粗品的精制方法 | |
| CN114014835A (zh) | 一种乙交酯的纯化工艺 | |
| CN114456223A (zh) | 3-缩酮的合成方法 | |
| CN117186163B (zh) | 一种三氯蔗糖-6-乙酸酯提纯工艺 | |
| CN117164493B (zh) | 维生素d3结晶的制备方法 | |
| CN116063364B (zh) | 一种药用级二丁酰环磷腺苷钠的制备方法 | |
| CN116199601B (zh) | 高含量百菌清的精制提纯工艺 | |
| CN113150044B (zh) | 一种硫氰酸红霉素的纯化方法 | |
| CN110981855B (zh) | 高残渣盐酸氨丙啉的提纯方法 | |
| CN120943765A (zh) | 一种骨化二醇粗品的结晶母液二次提取骨化二醇的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 050035 No. 518, Huai'an East Road, high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Patentee after: SHIJIAZHUANG NO.4 PHARMACEUTICAL Co.,Ltd. Patentee after: HEBEI GUANGXIANG PHARMACEUTICAL Co.,Ltd. Address before: 050035 No. 288 Pearl River Avenue, Shijiazhuang Hi-tech Industrial Development Zone, Hebei Province Patentee before: SHIJIAZHUANG NO.4 PHARMACEUTICAL Co.,Ltd. Patentee before: HEBEI GUANGXIANG PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230308 Address after: 061100 West District, Lingang Economic and Technological Development Zone, Cangzhou City, Hebei Province, east of Jingliu Road Patentee after: HEBEI GUANGXIANG PHARMACEUTICAL Co.,Ltd. Address before: 050035 No. 518, Huai'an East Road, high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Patentee before: SHIJIAZHUANG NO.4 PHARMACEUTICAL Co.,Ltd. Patentee before: HEBEI GUANGXIANG PHARMACEUTICAL Co.,Ltd. |